Introduction
Interleukin-7 (IL-7) is a 25-kDa glycoprotein involved in the regulation of lymphopoiesis. The thymic generation of T lymphocytes with a wide variety of antigen receptor specificities is dependent upon IL-7. Absence of functional IL-7 receptors (IL-7R) leads to severe combined immunodeficiency. 1 The maintenance of the peripheral pool of T cells is also dependent upon IL-7 through a process known as homeostatic proliferation. 2, 3 Recipients of allogeneic stem cell transplantation (SCT) suffer from a prolonged post transplant immune deficiency that results in significant morbidity and mortality. Reconstitution of the T-cell population involves both thymusdependent de novo T cell generation as well as extra-thymic expansion of mature, donor derived T cells. Recent studies in mice indicate that IL-7 may be critically involved in this process -not only by stimulating de novo T-cell generation, but also through stimulation of homeostatic proliferation of nonalloreactive donor T cells. 4 IL-7R consists of the gc-chain as well as an a-chain. The a-chain is also used by the receptor of thymic stromal lymphopoietin (TSLP), a cytokine with complex effects on cytokine profiles, including stimulation of TNF production by dendritic cells and the induction of Th2 cytokines. 5 Sequencing of IL-7Ra has revealed the existence of a range of single nucleotide polymorphisms (SNPs) ( þ 510C/T, þ 1237 A/G, þ 2087T/C and þ 3110A/G) which all result in amino-acid substitutions. 6 Preliminary data from our laboratories suggest that the AG and GG genotypes of the þ 1237 SNP are related to inhalation allergy. 7 The aim of the present investigation was to evaluate the significance of IL-7Ra SNPs for the outcome in allogeneic SCT. The presented data suggest that the donor genotype AG and GG at position þ 1237 is strongly associated with treatment-related mortality after SCT with matched unrelated donor (MUD).
Patients and methods

Patients
One hundred and ninety-five patients undergoing allogeneic SCT at the National University Hospital in Copenhagen during the period 20.6.88-16.6.03 were included in the study. The patients were selected by the availability of DNA from the donor. Patient DNA was available from only 192 of the 195 donor-recipient pairs. Patients with syngeneic donors were excluded. Patient and donor characteristics are listed in Table 4 .
Donors were either HLA identical siblings (n ¼ 120) or MUD (n ¼ 75).
A matched unrelated donor was defined as a donor who had either a low resolution match with the patient for HLA-A and HLA-B by serological typing and a high resolution match for DRB1* by genetyping (n ¼ 60) or a donor who had a high-resolution match for HLA-A, -B, -C, DRB1* and DQB1* by genetyping (n ¼ 15). Since the group who were partially matched by low-resolution may include donors with high-resolution mismatches on HLA class I and/or mismatch on DQB1, this group was analysed as a separate donor category in the analysis of transplant outcome.
The diagnoses included ALL (n ¼ 51), CML (n ¼ 52), AML (n ¼ 49), other haematological malignancies (n ¼ 17) and nonmalignant diseases (n ¼ 26, including six patients with SAA and 11 immune deficiencies).
The patients were transplanted with bone marrow (n ¼ 151) or peripheral blood stem cells harvested by leucopheresis from the donor after mobilization with G-CSF 10 mg/kg for five days (n ¼ 44).
The majority of patients were conditioned with total body irradiation (4 Gy for 3 days) and cyclophosphamide (n ¼ 126) or with busulphan and cyclophosphamide (n ¼ 64). All patients were treated with cyclosporine A with or without three or four doses of methotrexate as prophylaxis against graft-versus-host disease (GvHD). No ex vivo T-cell depletion was employed. All patients with unrelated donors and five patients with SAA who received bone marrow from HLA identical siblings received additional immunosuppression with anti-thymocyte globulin (ATG), ATGAM (20 mg/kg/day) or Thymoglobulin (2.5 mg/kg/day) for 3 days (day À5, À4 and À3 before the transplant).
The diagnosis of CMV infection was based on screening of blood by CMV antigen test or by CMV-PCR. Screening was performed weekly until day 120 after SCT and subsequently when clinically indicated.
Controls
Genomic DNA from 163 normal healthy, unrelated individuals were collected from the hospital staff and from students at the University of Copenhagen. The control subjects were all Scandinavian Caucasians.
Detection of IL-7Ra SNPs by sequence specific PCR (SSP) Genomic DNA from healthy individuals and patients was purified from 10 to 20 ml whole blood, stored in anticoagulant EDTA buffer, by use of QIAamp s DNA Blood Maxi Kit (QIAGEN).
The SSP-PCR reactions were set up in a total volume of 10 ml with control primer (0.2 mM) or specific primer (0.5 mM) ( Table 1) , approximately 50 ng genomic DNA, 0.2 mM dNTP, 1.5 mM MgCl 2 , PCR buffer (50 mM KCl, 20 mM Tris-HCl, pH 8.4), and 0.4 U of Taq polymerase. A GeneAmp PCR System 9700 (Applied Biosystems) was used. To each sample 2 ml loading buffer was added, and the samples were analysed in a 2.5% agarose gel stained with ethidium bromide ( Table 1) .
As control of the SSP-PCR systems DNA from 30 persons was sequenced in parallel with testing by SSP-PCR. The results of the two methods were identical.
Statistics
Differences between genotype frequencies of various groups were evaluated by the Fisher's exact test, by w 2 analysis and the Mann-Whitney test as appropriate.
Rates of overall post transplant survival were estimated by the Kaplan-Meier product-limit method. 8 For calculation of the hazard ratio (HR) of CMV infection, acute and chronic GvHD (cGvHD) and disease-free survival the patients were censored at relapse, death or at last followup. For calculation of the cumulative intensity of CMV infection and acute and cGvHD, the patients were censored at relapse, death or at last follow-up. Overall mortality was defined as death due to any cause including relapse. Treatment-related mortality was defined as death due to any cause in a patient who was in continuous remission of malignant disease after the transplant and was estimated by censoring at relapse or at last follow-up. Differences between groups of patients were tested by the log-rank test.
Multifactorial proportional hazards regression analysis was performed according to Cox to identify covariates associated with CMV infection, GvHD, treatment related Table 1 Sequences of primers for IL7Ra SSP-PCR typing . Acute and cGvHD and CMVinfection were entered as post transplant, time-dependent covariates. The effect of each covariate was expressed as the HR (denoting the probability of an event per unit of time relative to a reference group with HR ¼ 1). Interactions between covariates were analysed to identify patient groups who differed with respect to response to risk factors. All P-values were two-tailed. The level of significance was chosen to be 5%.
Ethics
The study was approved by the local ethics committee.
Results
IL-7Ra genotypes
The IL-7Ra genotype frequencies of patients and donors were comparable with those found in 173 healthy controls (Table 2) , and corresponded to previously reported gene frequencies. 6 The distribution of genotypes met the criteria for Hardy-Weinberg equilibrium.
Transplant outcome Twenty-nine of 100 patients with acute leukaemia had relapse of their disease and 26 patients died in continuous remission after the transplant. Seventy-five patients had at least moderate aGvHD, 74 patients had cGvHD of any grade. Thirty-one patients had CMV infection.
Univariate analysis of transplant outcomes according to IL-7Ra SNP types IL-7Ra þ 1237 genotypes of donor and mortality. Transplant outcome was analysed separately for transplants with MUD or sibling donors. The overall mortality in MUD transplants was found to be related to IL-7Ra polymorphism at position þ 1237, being highest in transplants with donors having the GG and AG genotypes and lowest for the AA genotype (P ¼ 0.023) (Figure 1a ). In contrast, the þ 1237genotype of the recipient appeared to be unrelated to mortality (Figure 1b) .
Analysis of treatment related mortality revealed a quite significantly increased mortality for MUD transplants with donor types AG and GG (P ¼ 0.003) ( Table 3 and Figure 2 ). In contrast, the risk of leukaemia relapse was unrelated to the þ 1237 polymorphism. In transplants with sibling donors the same pattern was seen, but the differences concerning treatment-related mortality were not significant (Table 3) . Table 4 shows the characteristics of subgroups of donorrecipient pairs selected for analysis of outcomes as described in the methods section. No significant differences were found between patients in the three different groups defined by donor þ 1237 genotypes.
þ 1237 genotypes of donor and aGvHD, cGvHD and CMV. There was no significant effect of donor IL-7Ra 1237 type on the probability of CMV infection and moderate-severe aGvHD. cGvHD was evaluated during the first year after transplantation. In MUD transplants IL-7Ra polymorphism in allogeneic stem cell transplantation Z Shamim et al there was no significant difference in the frequency of cGvHD between transplants with donors of the AA (cGvHD frequency 32%) and transplants with AG/GG donors (cGvHD frequency 41%), but cGvHD tended to occur later in patients with AA donors (median 179 days) than in patients with AG/GG donors (median 125 days) (P ¼ 0.18).
þ 1237 genotypes and immune reconstitution. The duration from transplant until to a lymphocyte count of 1 billion/l was achieved tended to be longer in MUD transplants with the donor genotypes AA/AG (median 64 days) than in transplants with AA donors (median 38 days) (P ¼ 0.07).
þ 1237 genotypes of the recipient. No association was observed between recipient IL-7Ra þ 1237 type and the probability of acute or cGvHD, CMV infection or relapse. Specifically, recipient genotype was not associated with treatment-related mortality (P ¼ 0.94). The number of donors and patients having the same genotype was very limited and did not allow any appropriate statistical evaluation of the combined effect of similar donor and recipient genotypes. The other IL-7Ra genotypes examined were not associated with the outcome after SCT (not shown).
Multiple Cox regression analysis of treatment-related mortality Table 5 shows the results of a multiple Cox regression analysis of transplantation-related mortality. In this model, donor IL-7Ra was analysed as a quantitative variable (zero, one and two A alleles). The HR denotes the relative risk of transplant-related death per unit of time per A allele. For a patient receiving a graft with the AG or the AA genotype, the relative risk was reduced to 0.51 and 0.26, respectively (Po0.02). Partially HLA-allele-typed unrelated donor was an additional risk factor (Po0.02) ( Table 5) . Variables tested for, but found insignificant in the model, included recipient IL-7Ra 1237 type, year of transplantation, age, diagnosis, high-risk stage, pretransplant CMV IgG status of donor and patient, unrelated donor matched for HLA-A,-B,-C, DRB1* and DQB1* by DNA-genotyping, female donor to male recipient, conditioning regimen including TBI and ATG, and inclusion of methotrexate in the GvHD prophylaxis (P ¼ 0.13). There was a trend that patient age increased the treatment-related mortality (P ¼ 0.13). A univariate analysis of these parameters analysed separately for patients having sibling donors and MUD did not demonstrate any significant associations.
When acute and cGvHD were entered as time dependent covariates, both were found to be associated with increased treatment related mortality (Po0.05 and Po0.01, respectively). The effect of donor IL-7Ra alleles remained significant (Po0.05), indicating that this covariate was associated with outcome even when GvHD was taken into account (Table 6 ). In this model, neither type of donor -HLA identical sibling or MUD -nor any other of the variables mentioned above was significant.
To address the question whether the effect of donor IL-7Ra genotype was restricted to subgroups of patients or potentiated in the presence of other risk factors, the interaction between number of A alleles with other variables were analysed in Cox models. No significant interactions were observed. However, a trend was observed for increased treatment-related mortality, when AA/AG donor type was combined with unrelated donor (P ¼ 0.08) or with post transplant CMV infection (P ¼ 0.07). Figure 2 Transplants with matched unrelated donors: treatment-related mortality after stem cell transplantation. Cumulated incidence plots showing the relation between IL-7Ra þ 1237 genotypes of the donor and treatment related mortality. Differences were tested for significance by the log-rank test.
Discussion
We have demonstrated an association between the IL-7Ra þ 1237 polymorphism and treatment-related mortality after SCT with matched unrelated donors. cGvHD tended to occur earlier in patients transplanted with AG/GG donors, but all over there was no significant difference during the first year after SCT. The IL-7Ra genotypes of the recipient were unrelated to the clinical outcome after SCT.
The functional impact of the IL-7Ra þ 1237 polymorphisms is not yet known. The IL-7Ra þ 1237 polymorphism gives rise to an amino-acid substitution in the extracellular part of the receptor, and it is conceivable that this polymorphism is associated with changes in the folded protein affecting either the domain binding IL-7 or influencing the interaction with the gc-chain and the intracellular signalling pathways. 10 Previous work has supported a model in which the gcchain serves primarily to transduce signals by the IL-7R complex, while the a-chain determines specific signalling events through its association with cytoplasmic signalling molecules 11 . In the present study, the association between IL-7Ra þ 1237 genotypes and the outcome after SCT was restricted to the donor genotype. This indicates that the observed association between mortality and IL-7Ra genotypes is related to the effect of IL-7 or TSLP on donor cells, and there are several mechanisms by which this may be accomplished.
First, IL-7 is essential for thymic maturation and for the homeostatic proliferation of lymphocytes. 12 Previous studies of SCT in mice and humans have suggested that T-cell reconstitution is dependent upon extra-thymic expansion of a Donor IL-Ra types GG, AG and AA were ascribed the value zero, one, and two, respectively. The reference group was donor GG genotype. HR denotes the hazard ratio per A allele. The reference group for the time dependent covariates, acute and chronic GvHD, was all patients without, or prior to onset of, acute or chronic GvHD, respectively.
IL-7Ra polymorphism in allogeneic stem cell transplantation Z Shamim et al mature T cells as well as on thymopoiesis. [13] [14] [15] Consequently, altered activity of IL-7 could influence the rate of immunoreconstitution and the diversity of the T-cell repertoire, including the development of autoreactive T cells. Indeed, reduced thymic function has been associated with increased occurrence of cGvHD, and there is evidence that IL-7 may preferentially stimulate the homeostatic proliferation of nonalloreactive T cells in transplanted mice. 4 There are, however, also data from other investigators indicating that treatment of mice with IL-7 leads to increased frequency of GvHD. 16 In our investigation, we did notice a trend towards a faster immune reconstitution in MUD transplants with the AA donor genotype. This may have an impact on the risk of both infections and GvHD, and it may therefore influence the risk of treatment-related mortality. A faster immune reconstitution could be due to either increased thymic production of T cells or increased proliferation of transplanted T cells. We are planning further studies of this including measurements of T-cell receptor excision circles.
Second, the a-chain polymorphisms may influence the outcome of SCT through effects on cytokine profiles. The a-chain is shared by TSLP that induces the production of Th2 cytokines. 17, 18 In transplants with þ 1237 AG/GG genotypes, we observed a trend towards earlier and more frequent occurrence of cGvHD that may be associated with a Th2 profile. 19 In line with this, we have previously found a significant association between þ 1237 AG/GG genotypes and inhalation allergy. 7 IL-7 and TSLP have been shown to induce the production of IL-8 and TNFa, respectively, 5, 20 and both cytokines are thought to play important pathogenetic roles in the development of treatment-related complications including aGvHD. [21] [22] [23] Thus, the observed relation between IL-7Ra polymorphism and mortality might also relate to an increased production of inflammatory cytokines.
MUD transplants differed from sibling donor transplants by the inclusion of ATG in the conditioning regimen. Based on the present data, it is not possible to judge to what degree the more severe immunosuppression associated with the use of ATG may potentiate the impact of IL-7Ra genotypes on the outcome in SCT. This question should be addressed in future studies of IL-7Ra genotypes.
In conclusion, the presented data suggest that the IL-7 pathway may be of pathogenetic importance for treatmentrelated mortality after SCT. If these findings are confirmed in studies of other cohorts of SCT patients, these findings would suggest selection of donors based on IL-7Ra genotyping, in addition to HLA-typing, in order to reduce treatment related mortality in SCT.
